DarioHealth

DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. It offers a monitoring device, mobile application, and data services for diabetes management. The firm solutions include MyDario, Daro Engage, and Dario Intelligence. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DarioHealth excels in Q4 2022 with B2B growth and strategic partnerships

DarioHealth's Q4 2022 marked strong financial performance and operational efficiency gains.
Strategic focus on B2B model and multi-condition management driving revenue growth.
Challenges include managing increased expenses and maintaining high gross margin targets.
Opportunities lie in expanding client base, strategic integrations, and revenue diversification.

DarioHealth reports revenue growth and strategic partnerships driving future expansion

DarioHealth's Q1 2023 performance showed revenue growth, improved margins, and strategic focus on B2B.
Strong partnerships with Amwell and Sanofi position the company for multi-condition agreements and revenue growth.
Operational challenges in DTC margins and user comparison require attention for sustained growth.
Opportunities lie in hospitalization reduction, revenue growth from partnerships, and market expansion through Aetna launch.

DarioHealth reports steady Q2 performance, eyes growth through partnerships

DarioHealth's Q2 2023 performance showcased steady B2B2C ARR growth despite flat revenue, with improving gross margins and reduced operating losses, supported by a strong cash position.
The company's strengths lie in strategic partnerships, market fit, and operational efficiency, while facing challenges in revenue growth rates and optimizing expenses.
Opportunities ahead include revenue growth through partnerships and new product launches, leveraging AI for engagement and cost efficiencies, and sustaining a software-driven business model.

DarioHealth reports growth in Q3 2023, eyes revenue diversification

DarioHealth's Q3 2023 showed growth and improved financial metrics.
Strategic partnerships and revenue diversification are key strengths.
Challenges include predicting revenue recognition and cost management.
Opportunities lie in revenue growth and becoming cash flow positive.

DarioHealth reports robust Q4 results, eyes growth through strategic acquisitions

DarioHealth's strong Q4 performance and strategic acquisitions position the company for growth in 2024 and 2025, with a focus on profitability and revenue expansion.
While facing challenges in revenue scaling and cost reduction, the company's strengths in cash position, innovation, and leadership integration provide a solid foundation for success.
Opportunities lie in revenue growth from partnerships and acquisitions, integration synergies, and advancements in digital solutions, driving DarioHealth's path to market differentiation and financial success.

DarioHealth excels in Q1 2024, eyes profitability post Twill merger

DarioHealth's strong Q1 performance driven by B2B2C growth, poised for profitability post Twill merger. Focus on product integration and revenue expansion in key channels.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DarioHealth Corp. is a digital health company which offers a user-centric and multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. DarioHealth serves customers globally. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.

DarioHealth has experienced a disappointing year with stalled revenue growth and a decline in new customer wins. However, H2/23 and FY24 are expected to bring improved financials, including revenue growth, expanded gross margins, and declining operating expenses. The company's competitive advantages include a customer-friendly platform, a multi-condition platform, and partnerships with important industry players.

DarioHealth Disappoints, But A Better Future Is Ahead

63% of members using the Dario platform saw significant reduction in depression and anxiety symptoms NEW YORK , Sept. 27, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced new research published in the Journal of Medical Internet Research (JMIR) demonstrating the impact of coaching and breathing exercises as part of the Dario digital behavioral health program alongside coaching and breathing exercises for members living with depression or anxiety.

Dario Publishes New Research Demonstrating Clinically Significant Reductions in Depression Through its Digital Behavioral Health Programs

New research presented at ADCES23 links engagement in Dario's digital health solutions with improved outcomes NEW YORK , Aug. 24, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced new research presented at the ADCES23 Annual Conference held earlier this month in Houston, Texas. The new research demonstrates Dario's ability to sustainably improve health outcomes for users with diabetes over a two-year period.

Dario Publishes New Research Demonstrating Greater Engagemenet and Improved Clinical Outcomes Sustainable for Two Years

New agreement expands Dario's reach in the employer market with access to more than 5 million consumers NEW YORK , Aug. 15, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced a new agreement with PlanSource, a leading provider of cloud-based benefits administration and engagement technology, to offer integrated digital health solutions to more than 5 million consumers.     Dario's solutions help employers address diabetes, pre-diabetes, hypertension, musculoskeletal and behavioral health needs in their populations with highly personalized solutions designed to optimize digital and human support driven by billions of data insights.

Dario Partners with PlanSource to Offer Employers Easy Access to Proven Digital Health Solutions

DarioHealth Corp. (NASDAQ:DRIO ) Q2 2023 Earnings Conference Call August 10, 2023 8:30 AM ET Company Participants Chuck Padala - Managing Director, Investor Relations Erez Raphael - Chief Executive Officer Rick Anderson - President Conference Call Participants Rahul Rakhit - LifeSci Capital Operator Greetings, and welcome to the DarioHealth Second Quarter 2023 Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

DarioHealth Corp. (DRIO) Q2 2023 Earnings Call Transcript

- Generated sequential B2B recurring revenue growth for the tenth consecutive quarter - Revenues of $6.15 million (pre-announced), compared to $6.18 million in the second quarter of 2022, a 0.5% decrease resulting from a delay with one of our strategic partners - Improved gross profit margin to 33.7% of revenues for the second quarter of 2023, up from 18.4% for the second quarter of 2022 - Improved proforma gross profit margin to 51.5% of revenues for the second quarter of 2023, up from 36.1% for the second quarter of 2022·  - Reduced operating expenses by 13% in the second quarter of 2023, as compared to the second quarter of 2022 - Launched hypertension solution with a large regional health plan through partnership with Solera and signed an expansion to that contract to include diabetes - Announced contract with pharmacy benefit manager, MedOne, through Dario's partnership with Sanofi - Cash and cash equivalents balance as of the end of the second quarter of 2023 of $52.6 million, which provides estimated runway through 2025 - Company to host investor conference call and webcast at 8:30 a.m. ET today NEW YORK , Aug. 10, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today reported financial results for the second quarter 2023 and provided a corporate and commercial update.

DarioHealth Reports Second Quarter 2023 Financial and Operating Results

Dario to provide support for members living with diabetes alongside existing hypertension solution NEW YORK , Aug. 8, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today the expansion of its agreement with a large regional health plan (the "Plan") to deliver highly personalized digital health solutions to Plan members living with diabetes with the launch anticipated to be in the first quarter of 2024. The Plan is adding Dario's support for diabetes to complement the current solution in place for hypertension.

Dario Expands Partnership with Large Regional Health Plan

Company to host conference call and webcast at 8:30am ET NEW YORK , Aug. 3, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital health  market, today announced that it will release its financial results for the second quarter ended June 30, 2023, on Thursday, August 10, 2023, before market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer and Rick Anderson, President, will host the call.

DarioHealth to Report Second Quarter 2023 Results on Thursday, August 10th

New program delivers whole health behavior change program to improve member health and deliver valuable insights to Dario's partners NEW YORK , Aug. 2, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced a new program today to deliver tailored behavior change support for individuals using GLP-1s and other anti-obesity drugs. The new program will help members realize the transformational power of these new medications while improving overall health and potentially help Dario's partners gain better insights on the impact across their populations.

Dario Introduces GLP-1 Behavior Change Program to Help Achieve Weight Loss Goals and Better Overall Health Outcomes

Retrospective cohort study demonstrated significant reduction in medical costs for Dario users with Type 2 diabetes compared to non-users driven by a significant reduction in in-patient hospitalizations after one year NEW YORK , July 26, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new analysis by Sanofi US demonstrating a significant reduction in the cost of care for Dario users compared to non-users living with Type 2 diabetes. The study used matched claims to show an estimated $5,077 in medical cost savings for Dario users compared to non-users.

New Research Shows $5,077 in Medical Costs Savings for Dario Users

New account is set to launch in July 2023 for eligible members NEW YORK , July 24, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new agreement with a large regional health plan (the "Plan") to deliver highly personalized digital health solutions to more than 160,000 Plan members living with hypertension. The Plan is set to launch in late July 2023.

Dario Launches Agreement with Large Regional Health Plan and Announces Preliminary Results for Second Quarter of 2023 as well as Business Update

New account anticipated to contribute to revenue in the second half of 2023 NEW YORK , July 6, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a new employer contract for the Company's full suite of integrated solutions. The new account is scheduled to launch in the second half of 2023.

Dario Announces New Full Suite Employer Contract

The market for digital healthcare is taking off and with its multi-condition platform, Dario is well-placed to take a slice of it. Their B2B strategy is winning them clients and partners like Aetna, Sanofi and Amwell, and a rapidly rising number of smaller employers and Health Plans.

6 Reasons To Buy Dario Health

Retrospective cohort study presented at the American Diabetes Association 83rd Scientific Sessions analyzed real-world data of Dario users against matched controls to demonstrate a greater reduction when compared to non-users who achieve a 1.8 point reduction with the usual standard of care NEW YORK , June 26, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today the presentation of research at the American Diabetes Association 83rd Scientific Sessions (the "Scientific Sessions") demonstrating significant reductions in HbA1c for Dario users compared to non-users. The study was conducted by Sanofi U.S. ("Sanofi") under its strategic agreement with Dario.

New Research Demonstrates 2.3 Point Reduction in HbA1c for Dario Digital Health Users with Baseline HbA1c Greater Than 9 points

DarioHealth Co. NASDAQ: DRIO is an AI-powered digital therapeutics platform and provider that adaptively personalizes monitoring and treatments for chronic diseases. The mobile app manages five common comorbidity conditions, including diabetes, weight loss, hypertension, musculoskeletal and behavioral health, across six domains: timing, tone, channel, content, frequency and intervention.

DarioHealth is an AI-Powered Digital Therapeutics Play

New accounts are anticipated to launch in the second half of 2023 NEW YORK , June 7, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new employer contracts for the Company's full suite of integrated solutions. The new accounts are scheduled to launch in the second half of 2023.

Dario Announces Two New Full Suite Employer Contracts

NEW YORK , June 1, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that the Company will participate in the Stifel 2023 Virtual Cross Sector Insight Conference, which is being held June 6-7, 2023, at The Intercontinental in Boston, MA. Rick Anderson, President of Dario, is scheduled to give a company presentation on Tuesday, June 6, 2023, at 4:45 PM EST.

Dario Management to Participate in the Stifel 2023 Virtual Cross Sector Insight Conference

Dario's health solution now available to MedOne clients enrolled in Diabetes Care Path NEW YORK , May 18, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global health market, and MedOne Pharmacy Benefit Solutions ("PBM"), a national leader in modern pharmacy benefits management, announce a new agreement to integrate Dario's suite of digital health solutions as a complement to MedOne's digital diabetes solution, the Diabetes Care Path. The new arrangement will enhance the patient-facing support services for diabetic patients while the MedOne clinical team focuses on interventions with prescribers to optimize treatment plans.

MedOne Launches Dario's Digital Health Solution to Help Members Improve Health with a Personalized Support

DarioHealth Corp. (NASDAQ:DRIO ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Chuck Padala - Managing Director, Investor Relations Erez Raphael - Chief Executive Officer Rick Anderson - President Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Charles Rhyee - Cowen Rahul Rakhit - LifeSci Capital Benjamin Haynor - Alliance Global Partners David Grossman - Stifel Financial Operator Good morning, and welcome to the DarioHealth First Quarter 2023 Results Call. All participants are in a listen only mode [Operator Instructions] After today's presentation, there will be opportunity to ask questions.

DarioHealth Corp. (DRIO) Q1 2023 Earnings Call Transcript

Sequential quarterly growth in revenue to $7.07 million Gross profit margin improving to 44.8% sequentially in the first quarter of 2023, up from 40.1% of revenues in the fourth quarter of 2022 Non-GAAP gross margin was 60.1% of revenues for the first quarter of 2023, up from 58.1% of revenues in the fourth quarter of 2022 Reduced cash used in operating activities in the first quarter to only $4.76 million Further reduced net loss to $12.8 million in Q1 2023, versus $15.9 million in Q1 2022, and $12.6 million in Q4 2022 Expanded strategic relationships by signing with Amwell and the first account through our relationship with Sanofi, a national pharmacy benefits manager Announced the presentation of the first Sanofi of Dario data which showed statistically significant reduction in all-cause health care resource utilization, including a 23.5% reduction in hospitalizations. Cash balance as of the end of Q1 of $38.8 million Proforma cash balance as of the end of Q1 inclusive of the private placement offering proceeds and the refinanced loan was $61 million Company to host investor conference call and webcast at 8:30 a.m.

DarioHealth Reports First Quarter Financial and Operating Results

Retrospective cohort study presented at ISPOR analyzed real-world data of users and non-users of a digital health solution NEW YORK , May 9, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today the presentation of research at ISPOR 2023 demonstrating significant reductions in healthcare resource utilization for Dario users compared to non-users, the first study completed by Sanofi U.S. ("Sanofi") under its strategic agreement with Dario. ISPOR, the leading global conference for health economics and outcomes research, is being held May 7 th – 10th in Boston.

Sanofi research demonstrates 9.3% reduction in all-cause healthcare resource utilization rates, including 23.5% decrease in hospitalization for Dario users

Company to host conference call and webcast at 8:30am ET NEW YORK , May 4, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital health market, today announced that it would release its financial results for the first quarter ended March 31, 2023, on Thursday, May 11, 2023, before market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer, Rick Anderson, President, and Zvi Ben-David, Chief Financial Officer will host the call.

DarioHealth to Report First Quarter 2023 Results on Thursday, May 11th

Newly designated convertible preferred stock priced at the market under Nasdaq rules with significant participation by select members of leadership, the Board and existing investors Company also announces refinancing of $25 million borrowed funds, saving approximately $6 million in annual amortization payments Proforma cash balance as of the end of Q1 inclusive of the private placement funds and the refinanced loan is $60M NEW YORK , May 2, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced the pricing of a $14.3 million private placement of convertible preferred stock, priced at the market under Nasdaq rules, with significant participation by select members of leadership, the Board and existing investors. The Company also announced the re-financing of its existing credit facility.

DarioHealth Announces $14.3 Million Private Placement

Dario also appoints digital veteran, Arnaud Robert, to the role of Strategic Advisor to the Chief Executive Officer The appointments strengthen Dario's ability to scale its digital therapeutics platform to meet growing market demand  NEW YORK , April 4, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) (the "Company" or "Dario"), a leader in the global digital therapeutics (DTx) market, announced today that digital health veteran, Eitan Shay, is joining the Company in the newly created position of Chief Product Officer. Mr. Shay previously held product leadership roles at digital health companies Livongo and Teladoc Health as well as senior leadership roles at Meta Platforms.

Digital Health Product Leader, Eitan Shay, Joins Dario as Chief Product Officer

New agreement is the first contract resulting from strategic partnership with Sanofi NEW YORK , March 27, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, announced a new contract with a leading nationwide Pharmacy Benefits Manager (the "PBM") operating in 50 states to provide Dario's digital therapeutics, starting with the diabetes solution, to employer clients beginning in the second quarter of 2023.   Through the new contract, the PBM will replace an existing digital diabetes solution with Dario's proven cardio metabolic digital therapeutic.

News for DarioHealth Stock (DRIO)